Evidence map›Paper›PMID 39434731›Full record

ArticleTranslational andrology and urology2024

Identifying

Hongwei Luo, Huichan He, Zezhen Liu, Yuting Liu, Feifei Hou, Yao Xie, Le Zhang, Jianming Lu, Shan Tang, Weide Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hongwei LuoGuangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huichan HeGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zezhen LiuGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yuting LiuDepartment of Urology, The Central Hospital of Shaoyang, Shaoyang, China.
Feifei HouDepartment of Urology, The Central Hospital of Shaoyang, Shaoyang, China.
Yao XieDepartment of Urology, The Central Hospital of Shaoyang, Shaoyang, China.
Le ZhangInstitute for Integrative Genome Biology, University of California, Riverside, CA, USA.
Jianming LuDepartment of Andrology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Shan TangDepartment of Urology, The Central Hospital of Shaoyang, Shaoyang, China.
Weide ZhongGuangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-0430-2845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cell carcinoma (RCC) is a heterogeneous disease. Identifying effective biomarkers is crucial for improving prognostic accuracy and therapy outcomes. This study investigates cell division cycle-associated 3 ( Methods: This study analyzed multi-omics data from The Cancer Genome Atlas (TCGA) for kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and kidney chromophobe (KICH) subtypes to evaluate Results: Higher Conclusions:

Indexed as

biomarkerCell division cycle-associated 3 (CDCA3)immunotherapyprognosisrenal cell carcinoma (RCC)

Identifiers

PMID39434731
PMCPMC11491202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.